Xbrane Biopharma AB - Asset Resilience Ratio
Xbrane Biopharma AB (XBRANE) has an Asset Resilience Ratio of 12.89% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Xbrane Biopharma AB working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2016)
This chart shows how Xbrane Biopharma AB's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Xbrane Biopharma AB total assets.
Liquid Assets Composition Over Time
This chart breaks down Xbrane Biopharma AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read XBRANE current and long-term liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr86.59 Million | 12.89% |
| Short-term Investments | Skr0.00 | 0% |
| Total Liquid Assets | Skr86.59 Million | 12.89% |
Asset Resilience Insights
- Moderate Liquidity: Xbrane Biopharma AB has 12.89% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Xbrane Biopharma AB Industry Peers by Asset Resilience Ratio
Compare Xbrane Biopharma AB's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Dianthus Therapeutics Inc.
NASDAQ:DNTH |
Biotechnology | 63.98% |
|
Tango Therapeutics Inc
NASDAQ:TNGX |
Biotechnology | 62.24% |
|
Damora Therapeutics, Inc.
NASDAQ:DMRA |
Biotechnology | 0.00% |
|
Wecome Pharmaceutical Co Ltd
SHE:300878 |
Biotechnology | 0.67% |
|
Tectonic Therapeutic, Inc.
NASDAQ:TECX |
Biotechnology | 86.66% |
|
Relmada Therapeutics Inc
NASDAQ:RLMD |
Biotechnology | 95.25% |
|
MediWound Ltd
F:M8W |
Biotechnology | 56.04% |
Annual Asset Resilience Ratio for Xbrane Biopharma AB (2016–2016)
The table below shows the annual Asset Resilience Ratio data for Xbrane Biopharma AB.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2016-12-31 | 26.53% | Skr31.34 Million ≈ $3.37 Million |
Skr118.11 Million ≈ $12.71 Million |
-- |
About Xbrane Biopharma AB
Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. It offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adu… Read more